Lineage Cell Therapeutics, Inc.

AMEX:LCTX

Biotechnology

Healthcare
$0.84 -2.80%

-$0.04 today

Market cap
$212.10M
Beta
1.51
P/E (TTM)
-4.6
EPS (TTM)
-$0.26
52W Low $0.85High $2.09

Volume 1.22M

Average 1.19M

LCTX Other Investing Activities

Investing cash flows not reported separately.

Lineage Cell Therapeutics, Inc.AMEX: LCTX

Other Investing Activities · Q1 FY2026 · quarter ended Mar 2026

Other investing activities outflow grows to $0

Q1 FY2026 other investing activities was $0, compared with $0 a year earlier. Trailing-twelve-month other investing activities was -$288K.

Context

  • Other investing activities amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Other investing activities increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other investing activities holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$72K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0+100.0% QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
-$288K+44.0% YoY
Other Investing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Investing Activities history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Other Investing Activities vs competitors

How LCTX compares with its peers on the latest reported figures

  • LCTX's LTM Mar 2026 other investing activities of $288K is the 2nd largest of the 4 companies compared; the peer median is $43.5K.
  • Its year-over-year change of +44.0% is the highest of 4, against a peer median of -108.0%.
  • Other investing activities amounts to 1.9% of revenue for LCTX, versus a peer median of 0.0%.
LCTX Competitors Peer median
Other Investing Activities for LCTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IPSCCentury Therapeutics, Inc.LTM Mar 2026$4.25M -112.9%-4.0%—
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$288K +44.0%—1.9%
MESOMesoblast LimitedLTM Jun 2026$43.5K -108.0%—0.0%
CELUCelularity Inc.LTM Dec 2025$0 -100.0%—0.0%
Peer median (excluding LCTX) $43.5K-108.0%-4.0%0.0%

Competitors are the stored peer set for LCTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(43.27M)(26.35M)(21.49M)(18.61M)(63.53M)
Depreciation & Amortization873K727K692K609K699K
Deferred Income Tax(6M)0(1.8M)0(5.28M)
Stock-Based Compensation3.52M4.29M4.64M5.08M4.75M
Change in Working Capital21.11M18.67M(10.8M)(8.77M)(4.11M)
Accounts Receivables(857K)50.31M(446K)106K(316K)
Inventory(72K)0000
Accounts Payables21.65M(18.7M)(2.3M)(1.68M)2.27M
Other Working Capital308K(12.94M)(8.06M)(7.19M)(6.07M)
Other Non-Cash Items202K3.73M195K(1.4M)48.55M
Operating Cash Flow(23.56M)1.06M(28.57M)(23.09M)(18.92M)
Capital Expenditures(354K)(413K)(674K)(565K)(522K)
Acquisitions (Net)10.09M45.75M000
Purchases of Investments6.02M(53.41M)(16.4M)(8.76M)(14.94M)
Sales of Investments(6.02M)7.67M63.53M7.02M2M
Other Investing Activities14K(45.75M)000
Investing Cash Flow9.75M(46.16M)46.45M(2.31M)(13.46M)
Debt Repayment(20K)(32K)(54K)(54K)(59K)
Common Stock Issued30.87M148K6.63M35.88M27.03M
Common Stock Repurchased(54K)(17K)(37K)(23K)0
Dividends Paid00000
Other Financing Activities6.14M1.53M(37K)58K(16K)
Financing Cash Flow36.93M1.63M6.42M35.86M26.95M
Effect of Forex Changes(20K)(873K)(250K)(95K)396K
Net Change in Cash23.09M(44.34M)24.06M10.36M(5.03M)
Free Cash Flow(23.92M)646K(29.24M)(23.66M)(19.44M)

Lineage Cell Therapeutics, Inc.

AMEX:LCTX

Intrinsic Alpha fair value

Locked

Current Price

$0.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.